Recently, the new selective mineralocorticoid receptor antagonist (MRA) Eplerenone tablets developed by Grand Pharmaceutical Group in cooperation with Nanjing Cavendish Bio-Engineering Technology Co., Ltd. have obtained the drug license issued by the National Medical Products Administration.
Our Group’s Eplerenone tablets are the exclusive product on the domestic market. The successful registration of the product on the domestic market has made up for the gap of second-generation MRA drugs in China. The clinical use of MRA drugs for the treatment of cardiovascular diseases such as heart failure and hypertension has been recommended by various medical guidelines and experts. In the current used of MRA drugs, Eplerenone has a higher selectivity of MR. This product is safe and effective as a new generation MRA drug with fewer side effects.
The Board of Directors of Grand Pharmaceutical Group said: ‘In the future, our Group will consistently increase our investment in research and development of innovative products and advanced technologies, and enrich and improve our product pipeline and industrial area. Our Group believes in the strategy of “globalised operation and dual circulation development”, and takes full advantage of our industrial strengths and research capabilities. In accelerating the development of innovative products into the market, our Group aims to provide global patients with more advanced and diversified treatment solutions.’
